ðə lˈɪkwɪd fˌɔːɹmjʊlˈeɪʃən wʌz wɪθdɹˈɔːn bɪkˈʌz əvən ˈʌpwɚd tɹˈɛnd ɪn spɑːntˈeɪniəs ɹᵻpˈoːɹts ʌv ædvˈɜːs ɹɪˈækʃənz, ɪŋklˈuːdɪŋ sˈɪŋkoʊp fˈeɪntɪŋ, wˌɪtʃ ɑːɹ tˈɛmpɚɹəli kˈɔɹɪlˌeɪɾᵻd wɪð ɐ tʃˈeɪndʒ ðæt wʌz mˌeɪd tə ðə fˌɔːɹmjʊlˈeɪʃən ɚɹˈaʊnd ˈeɪpɹəl tˈuː θˈaʊzənd sˈɛvən tʊ ɪŋklˈuːd ˈɛdɪtˌeɪt dɪsˈoʊdiəm ˈɛdtə.
The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change that was made to the formulation around April 2007 to include edetate disodium (EDTA).